- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
18.81
+0.11(+0.59%)
Closed
Pre Market
18.79-0.02(-0.11%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.66
19.13
52 wk Range
5.12
20.33
TVTX Income Statement
Featured here, the Income Statement (earnings report) for Travere Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
Advanced Income Statement
| Period Ending: | 2014 31/12 | 2015 31/12 | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 175.34 | 198.32 | 131.84 | 109.46 | 145.24 | |||||||||
Total Revenues Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | +6.75% | +13.11% | -33.52% | -16.97% | +32.69% | |||||||||
Cost Of Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 146.2 | 137.9 | 204.98 | 231.75 | 256.44 | |||||||||
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 29.14 | 60.42 | -73.14 | -122.29 | -111.2 | |||||||||
Gross Profit Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -81.64% | +107.34% | -221.05% | -67.2% | +9.07% | |||||||||
Gross Profit Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 16.62% | 30.47% | -55.48% | -111.72% | -76.57% | |||||||||
Other Operating Expenses, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 128.95 | 135.8 | 126.28 | 197.52 | 265.54 | |||||||||
| |||||||||||||||||||
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -99.81 | -75.38 | -199.43 | -319.81 | -376.74 | |||||||||
Operating Income Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -45.3% | +24.48% | -164.57% | -60.37% | -17.8% | |||||||||
EBIT Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -56.92% | -38.01% | -151.27% | -292.17% | -259.4% | |||||||||
Net Interest Expenses | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -8.77 | -14.05 | -17.69 | -4.74 | 10.43 | |||||||||
Net Interest Expenses Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -103.5% | -60.12% | -25.93% | +73.21% | +320.22% | |||||||||
Interest Expense, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -18.83 | -19.05 | -19.68 | -11.01 | -11.33 | |||||||||
Interest And Investment Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 10.06 | 5 | 1.99 | 6.28 | 21.77 | |||||||||
Other Non Operating Expenses, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -0.31 | 1.42 | 0.23 | 0.97 | 1.59 | |||||||||
EBT, Excl. Unusual Items | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -108.9 | -88 | -216.88 | -323.58 | -364.72 | |||||||||
Gain (Loss) On Sale Of Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Other Unusual Items, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -22.55 | -100.79 | - | -7.58 | - | |||||||||
EBT, Incl. Unusual Items | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -146.45 | -188.79 | -216.88 | -331.16 | -376.11 | |||||||||
EBT, Incl. Unusual Items Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -43.76% | -28.91% | -14.88% | -52.69% | -13.58% | |||||||||
EBT, Incl. Unusual Items Margin | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -83.52% | -95.19% | -164.51% | -302.54% | -258.96% | |||||||||
Income Tax Expense | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -0.02 | -19.36 | 0.41 | 0.31 | 0.22 | |||||||||
Net Income to Company | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -146.43 | -169.43 | -180.09 | -278.48 | -111.4 | |||||||||
Minority Interest | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -146.43 | -169.43 | -180.09 | -278.48 | -111.4 | |||||||||
Net Income Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -42.61% | -15.71% | -6.29% | -54.63% | +60% | |||||||||
Net Income Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -83.51% | -85.43% | -136.6% | -254.41% | -76.7% | |||||||||
Preferred Dividend and Other Adjustments | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income to Common Excl. Extra Items | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -146.43 | -169.43 | -217.29 | -331.47 | -376.33 | |||||||||
Basic EPS - Continuing Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -3.46 | -3.56 | -3.63 | -5.2 | -5.07 | |||||||||
Basic EPS - Continuing Operations Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -36.19% | -3.05% | -1.9% | -43.15% | +2.53% | |||||||||
Diluted EPS - Continuing Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -3.46 | -3.56 | -3.63 | -5.2 | -5.07 | |||||||||
Diluted EPS - Continuing Operations Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -36.16% | -3.05% | -1.9% | -43.15% | +2.53% | |||||||||
Basic Weighted Average Shares Outstanding | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 42.34 | 47.54 | 59.83 | 63.76 | 74.27 | |||||||||
Diluted Weighted Average Shares Outstanding | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 42.34 | 47.54 | 59.83 | 63.76 | 74.27 | |||||||||
Dividend Per Share | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Dividend Per Share Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
EBITDA | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -79.4 | -50.8 | -186.68 | -299.09 | -338.21 | |||||||||
EBITDA Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -58.73% | +36.02% | -267.49% | -60.22% | -13.08% | |||||||||
EBITDA Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -45.29% | -25.61% | -141.6% | -273.25% | -232.87% | |||||||||
EBIT | aa.aa | aa.aa | aa.aa | aa.aa | |||||||||||||||